Natco Pharma has launched a new generation anti-migraine drug called Rizatriptan in a pack of 5 mg / 10 mg tablets. According to a release issued to the BSE, Rizatriptan, which has been lauched under a brand name of Ritza, is a new generation anti-migraine drug and is considered more effective than the traditional triptans.The total migraine market in India is substantial, and is growing at the rate of 25% per annum. Rizatriptan provides relief within one hour of the intake of the medicine from migraine. A 10 mg tablet of Rizatriptan is equipotent to a 100 mg tablet of Sumatriptan the traditional anti migraine drug. The company has priced Ritza competitively at around Rs 30 for a 10 mg. tablet and at around Rs 20 for a 5 mg. tablet and is cheaper than the other brands available in the market. Ritza, thus, becomes the most affordable drug in its class.The company expects to garner a substantial market share in the very first year of launch, the release further added.
